Assenagon Asset Management
SMMT icon

Assenagon Asset Management’s Summit Therapeutics SMMT Stock Holding History

Assenagon Asset Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$869K Hold
59,621
– – ﹤0.01% 993
2026
Q1 		$1.13M Hold
59,621
– – ﹤0.01% 868
2025
Q4 		$1.04M Buy
+59,621
New +$1.12M ﹤0.01% 928
2025
Q1 		– Sell
-12,824
Closed -$229K – 1324
2024
Q4 		$229K Buy
+12,824
New +$249K ﹤0.01% 1272

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Assenagon Asset Management's SMMT Position: Q2 2026 in Review

Assenagon Asset Management held its Summit Therapeutics (SMMT) position steady in Q2 2026 at 59,621 shares worth $869K. The position accounts for ﹤0.01% of the portfolio, ranked #993.

Assenagon Asset Management first reported a position in SMMT in Q4 2024 and has held it in 4 quarters since. The position peaked at $1.13M in Q1 2026. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Assenagon Asset Management held 59,621 shares of Summit Therapeutics worth $869K as of Q2 2026.
  • Assenagon Asset Management left its Summit Therapeutics share count unchanged in Q2 2026.
  • Summit Therapeutics made up ﹤0.01% of Assenagon Asset Management's portfolio in Q2 2026, its #993 holding.
  • Assenagon Asset Management first reported a position in Summit Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • Assenagon Asset Management's Summit Therapeutics position peaked at $1.13M in Q1 2026.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.